A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil

Anticancer Research

Volumn 31, Issue 2, 2011, Pages 625-632

  Saif, M Wasif ^a   Rosen, L S ^b   Saito, K ^c   Zergebel, C ^c   Ravage Mass, L ^a   Mendelson, D S ^d  

^a Herbert Irving Cancer Center ^*  (United States)

^b Premiere Oncology   (United States)

^c Taiho Pharma USA Inc   (United States)

^d Pinnacle Oncology Hematology   (United States)

Author keywords

5 Fluorouracil; CDHP; DPD; FBAL; FT; Gimeracil; Phase I; Reversible dihydropyrimidine dehydrogenase; S 1; Solid tumors; Tegafur

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ALPHA FLUORO BETA ALANINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG INHIBITION; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG URINE LEVEL; DRUG WITHDRAWAL; EVENING DOSAGE; FATIGUE; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SOLID TUMOR; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CROSS-OVER STUDIES; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; OXONIC ACID; PYRIDINES; TEGAFUR;

EID: 79953237769     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Diasio RB and Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16: 215-237, 1989.
2. Iyer L and Ratain MJ: 5-Fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy. Cancer Investig 17: 494-506, 1999. (Pubitemid 29458122)
3. Diasio RB: Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines. Drugs 58: 119-126, 1999.
4. Tatsumi K, Fukushima M, Shirasaka T et al: Inhibitory effect of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts Jpn J Cancer Res 78(7): 748-755, 1987.
5. Saif MW, Syrigos KN and Katirtzoglou NA: S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs 18(3): 335-348, 2009.
6. Shirasaka T, Shimamoto Y, Ohshimo H et al: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7(5): 548-557, 1996. (Pubitemid 26276346)
7. Takechi T, Nakano K, Uchida J et al: Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 39(3): 205-211, 1997. (Pubitemid 26414256)
8. Fukushima M, Shimamoto Y, Kato T et al: Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil. Anticancer Drugs 9(9): 817-823, 1998. (Pubitemid 28512890)
9. Hirata K, Horikoshi N, Aiba K et al: Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5(8): 2000-2005, 1999.
10. Sakuramoto S, Sasako M, Yamaguchi T et al: ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357(18): 1810-1820, 2007.
11. Koizumi W, Narahara H, Hara T et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3): 215-221, 2008.
12. Kato K, Muro K, Yasui H et al: The FIRIS study; A Phase III trial of 5FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as 2nd-line chemotherapy for metastatic colorectal cancer (mCRC) [FIRIS study group] Eur J Cancer Suppl 7(2): 324, 2009.
13. Ajani JA, Rodriguez W, Bodoky G et al: Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 28(9): 1547-1553, 2010.
14. Zhu AX, Clark JW, Ryan DP et al: Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. Cancer Chemother Pharmacol 59(3): 285-293, 2007. (Pubitemid 46025515)
15. Therasse P, Arbuck SG, Eisenhauer EA et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000. (Pubitemid 30099779)
16. Poorter RL, Peters GJ, Bakker PJ et al: Intermittent continuous infusion of 5-fluorouracil and low dose oral leucovorin in patients with gastrointestinal cancer: relationship between plasma concentrations and clinical parameters. Eur J Cancer 31A(9): 1465-1470, 1995.
17. Pinedo HM and Peters GF: Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6(10): 1653-1664, 1988.
18. van Groeningen CJ, Pinedo HM, Heddes J et al: Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res 48(23): 6956-6961, 1988. (Pubitemid 19012233)
19. Zhu AX, Clark JW, Ryan DP et al: Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. Cancer Chemother Pharmacol 59(3): 285-293, 2007. (Pubitemid 46025515)
20. Hirata K, Horikoshi N, Aiba K et al: Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5: 2000-2005, 1999.
21. Baker SD, Diasio RB, O'Reilly S et al: Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. J Clin Oncol 18: 915-926, 2000. (Pubitemid 30106624)
22. Adjei AA, Reid JM, Diasio RB et al: Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumours. J Clin Oncol 20: 1683-1691, 2002. (Pubitemid 34260551)
23. Peters GJ, Noordhuis P, Van Kuilenburg AB et al: Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumours. Cancer Chemother Pharmacol 52: 1-12, 2003. (Pubitemid 36920622)
24. Nemunaitis J, Eager R, Twaddell T et al: Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumours. J Clin Oncol 18: 3423-3434, 2000.
25. Petit E, Milano G, Levi F et al: Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five day continuous venous infusion at a constant rate in cancer patients. Cancer Res 48: 1976-1979, 1988.
26. Ho DH, Pazdur R, Covington W et al: Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2′-tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res 4: 2085-2088, 1998. (Pubitemid 28415651)
27. Muggia FM, Wu X, Spicer D et al: Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil. Clin Cancer Res 2: 1461-1467, 1996. (Pubitemid 126447438)